Surgical outcomes and prognostic factors influencing long-term survival in patients with gallbladder cancer

Sung Ha Lee, Jae Do Yang, Hong Pil Hwang, Hee Chul Yu, and Baik Hwan Cho

Department of Surgery, Chonbuk National University Medical School and Hospital, Jeonju, Korea

Backgrounds/Aims: The aim of this study is to analyze surgical outcomes and prognostic factors affecting survival after surgical resection in patients with gallbladder cancer. Methods: We retrospectively reviewed 86 patients treated surgically for gallbladder cancer from January 2000 to December 2009 at Chonbuk National University Hospital. Clinicopathologic factors, surgical treatment and outcome data were analyzed. Results: Among the 86 patients (44 male, 42 female) with gallbladder cancer, the mean age was 62.9 years (range: 32-80) and the median survival was 42.4±3.5 month. The overall cumulative survival rates of 86 patients were for 1 year, 83.7%; 3 year, 67.4%; 5 year survival, 61.7%. Univariate analysis revealed that preoperative serum alanine aminotransferase, alkaline phosphatase, total bilirubin, carcinoembryonic antigen (CEA), T staging, N staging were statistically significantly associated with survival. CEA ($p=0.004$) and T staging ($p=0.005$) were associated with survival in multivariate analysis. Two-year survival rates were analyzed according to the methods of surgical resection, with simple cholecystectomy showing 100%, whereas extended cholecystectomy showed about 83% in T1b. We could not find out any adverse effect of the simple cholecystectomy for survival. Conclusions: CEA and T stage are independent significant prognostic factor associated with patient survival in our study. Simple cholecystectomy can be regarded as curative resection in stage T1b. Longer observation periods and more cases will be needed to confirm these conclusions. (Korean J Hepatobiliary Pancreat Surg 2012;16:59-64)

Key Words: Gallbladder cancer; Prognostic factors; Survival rate
analyzed. Stages of the cancer were classified according to the American Joint Committee on Cancer (AJCC) 7th edition. Curative resection defined as simple cholecystectomy with no remnant cancer on permanent pathologic report in Tis and T1a, and radical cholecystectomy combined hepatectomy or not with no remnant cancer on permanent pathologic report in T1b, T2 and T3.

Univariate analysis was performed using the Kaplan-Meier method and compared with the log-rank test. Multivariate analysis was performed using the Cox regression hazards model to identify independent prognostic factors. All statistical analyses used SPSS 18.0 for Windows (SPSS Inc. Chicago, Ill). A p-value less than 0.05 was considered statistically significant.

### RESULTS

#### Age and gender distribution

Of the 86 patients, gender distribution is similar, 44 male and 42 female. Mean age was about 62.9 years, with a range of 32 to 80. Highest prevalence was seen in the 5th decade, 29 cases (33.7%).

#### Survival rates according to clinical factors

Preoperative serum aspartate aminotransferase (AST), alanine aminotransferase (ALT), total bilirubin (T-bil), direct bilirubin (D-bil), alkaline phosphatase (ALP), Gamma-glutamyl transferase (GGT), carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA 19-9) were analyzed, and among these factors, ALT, ALP, T-bil, and CEA showed a statistically significant association with 5-year survival in univariate analysis (Table 1).

#### Survival rates according to T stage and N stage

T stage and N stage were classified by the 7th AJCC classification system, with 6 cases of Tis (7.0%), 5 cases of T1a (5.8%), 13 cases of T1b (15.1%), 32 cases of T2 (37.2%), 26 cases of T3 (30.2%) and 4 cases of T4 (4.7%). According to T stage, the 5-year survival rate decreased as stages increased. Tis and T1a showed 100% 5-year survival rate, and T1b showed 84.6%, T2 61.4%, T3 40.9%, T4 0% survival rate. All 11 patients of the Tis and T1a stages showed more than 10 year survival ($p=0.000$) (Fig. 1).

Excluding 30 patients (34.9%) who did not undergo surgery, survival analysis was performed using the Kaplan-Meier method. Mean survival time was 35.9 months, with a range of 0 to 150 months. A p-value less than 0.05 was considered statistically significant.

### Table 1. Survival according to clinical factors of patients

| Variable          | No. of patient (%) | 5-year survival (%) | p    |
|-------------------|--------------------|---------------------|------|
| Gender            |                    |                     |      |
| Male              | 44 (51.2)          | 59.9                | 0.287|
| Female            | 42 (48.8)          | 64.5                |      |
| AST (IU/L)        |                    |                     |      |
| > 40              | 9 (10.5)           | 37                  | 0.133|
| ≤ 40              | 77 (89.5)          | 61.5                |      |
| ALT (IU/L)        |                    |                     |      |
| > 40              | 15 (17.4)          | 36.7                | 0.05 |
| ≤ 40              | 71 (82.6)          | 68.2                |      |
| T-bil (mg/dl)     |                    |                     |      |
| > 1.2             | 5 (5.8)            | 0                   | 0.021|
| ≤ 1.2             | 81 (94.2)          | 64.7                |      |
| D-bil (mg/dl)     |                    |                     |      |
| > 0.4             | 7 (8.1)            | 57.1                | 0.834|
| ≤ 0.4             | 59 (68.6)          | 61.1                |      |
| ALP (IU/L)        |                    |                     |      |
| > 300             | 15 (17.4)          | 35.6                | 0.011|
| ≤ 300             | 68 (79.1)          | 65.4                |      |
| GGT (IU/L)        |                    |                     |      |
| > 75              | 14 (16.3)          | 40                  | 0.061|
| ≤ 75              | 52 (60.5)          | 69.5                |      |
| CEA (ng/ml)       |                    |                     |      |
| > 10              | 7 (8.1)            | 28.6                | 0.007|
| ≤ 10              | 64 (74.4)          | 60.3                |      |
| CA19-9 (U/ml)     |                    |                     |      |
| > 40              | 23 (26.7)          | 45.8                | 0.157|
| ≤ 40              | 51 (59.3)          | 64.7                |      |

AST, aspartate aminotransferase; ALT, alanine aminotransferase; T-bil, total bilirubin; D-bil, direct bilirubin; ALP, alkaline phosphatase; GGT, Gamma-glutamyl transferase; CEA, carcinoembryonic antigen; CA19-9, carbohydrate antigen 19-9.

![Fig. 1](image-url) Cumulative survival rates related to T stage (AJCC 7th edition).
lymph node dissection, 56 patients were classified according to the N stage of the 7th AJCC classification. Results were 32 cases (37.2%) of N0, 17 cases (19.8%) of N1, and 7 cases (8.1%) of N2 stages. The 5-year survival rates according to N stage were 80.6% in N0, 27.6% in N1, and 19.0% in N2 (p=0.003) (Fig. 2).

**Prognostic factors**

ALT, ALP, T-bil and CEA, T and N stage were significant factors on univariate analysis.

Of these factors, CEA and T stage were statistically significant independent prognostic factors on multivariate analysis (Table 2).

**Survival rates according to surgical method in T stage**

Of the 86 cases, 60 cases underwent curative resection, while 26 cases were operated palliatively. In the curative resection groups, the survival rates were 1-year (90.0%), 3-year (77.0%), and 5-year (72.1%). Survival in the palliative resection group was 1-year 69.2%; 3-year 42.3%; and 5-year 33.8%. These suggested a higher survival rate in curative resection (p=0.000) (Fig. 3).

Comparison between curative and palliative resection was carried out in the T1b, T2, and T3 groups. Tis and T1a groups, in which only curative resection were performed, were not comparable and therefore excluded, along with the T4 groups, in which no case was treated with curative resection at all.

**Survival in patients with T1b tumor**

In group T1b, excluding one case where second-look operation was rejected despite a positive margin of cancer on the cystic duct, 6 cases of simple cholecystectomy and 6 cases of extended cholecystectomy were compared. Medial survival was 54.7±33.8 months in the simple cholecystectomy subgroup, and 32.0±19.7 months in the extended cholecystectomy subgroup, with no statistically significant difference. During the observation period, one patient expired due to liver metastases 15 months after extended cholecystectomy. 2-year survival rates were compared according to surgical method. All of the simple cholecystectomy subgroup survived, while in the extended cholecystectomy subgroup 83.3% survived.

**Survival in patients with T2 tumor**

Twenty-four cases of curative resection and 8 cases of palliative resection were performed in the T2 group (3 cases in which second-look operations were not performed; 3 cases in which lymph node dissection was not performed; and 2 cases in which only simple cholecystectomy was performed).

| Variables | Univariate p-value | Multivariate p-value |
|-----------|--------------------|----------------------|
| ALT (IU/L) | 0.05               | 0.889                |
| T-bil (mg/dl) | 0.021              | 0.986                |
| ALP (IU/L) | 0.011              | 0.469                |
| CEA (ng/ml) | 0.007              | 0.004                |
| T stage | 0.000              | 0.005                |
| N stage | 0.003              | 0.055                |

ALT, alanine aminotransferase; T-bil, total bilirubin; ALP, alkaline phosphatase; CEA, carcinoembryonic antigen
Cumulative survival rates related to stage system (AJCC 7th edition).

**DISCUSSION**

Despite increased early detection through the development of preoperative diagnostic tools, greater acceptance of routine health checkups, and increased survival rate through advanced operative procedures and post-operative care, gallbladder cancer still has a poor prognosis, especially since many patients are inoperable at diagnosis.3,4

In a study of 724 cases carried out by the French Surgical Association in 1994, the median survival period was 3 months, and 5 year survival rates were 5%.5 Konstantinidis et al.6 reported a 40-year follow-up study which showed median survival of 3.5 months between 1962 and 1979, 6.5 months between 1980 and 1997, and 12 months between 1998 and 2008. Liang et al.7 reported a 25 year follow-up study which showed median survival of 12.3 months and survival rates at 1 year (50.5%), 3 years (29.5%), and 5 years (26.2%). In our study, comparable survival rates are 1 year (83.7%), 3 years (67.4%), and 5 years (61.7%).

Various clinical prognostic factors in gallbladder cancer have been reported. Generally, incidence is 2 to 6 times higher in women, which is probably due to the fact that cholelithiasis is more frequent in women. Despite the lower incidence rate, male gender is a poor prognostic factor, showing shorter median survival periods.2,8 There was no survival difference according to gender in our study.

There are no characteristic symptoms in early gallbladder cancer, but as disease progresses various symptoms arise, generally showing poorer prognosis with acute/chronic cholecystitis or focal biliary complications.9 In our study, poorer prognosis was observed when there were abnormal results in the liver function tests, such as ALT, bilirubin, and ALP, in univariate analysis.

CEA is a typical tumor marker elevated not only in gallbladder cancer but also in colon cancer and other types of cancer. Chakravarty et al.10 reported that serum CEA levels were independent prognostic factors that affect long-term survival regardless of T stage. Likewise, CEA was an independent prognostic factor in our study. CA19-9 is a tumor marker frequently elevated in gallbladder cancer, especially associated with intra-epithelial dysplasia and adenocarcinoma. It has been reported to show significant association with other important prognostic factors such as a history of jaundice and lymph.
node metastasis. Study to distinguish CA19-9 as a prognostic factor in gallbladder cancer has been insufficient, and in our study there was no association in univariate analysis.

The major principle in treatment of gallbladder cancer is surgical resection, with radiation therapy, chemotherapy, immunotherapy as optional choices, although effectiveness is meager. Recently, there has been a tendency towards determining surgical methods in gallbladder cancer according to T stage. 

Tis and T1a have shown complete remission with simple cholecystectomy alone. In our study, all cases of Tis and T1a cancers were treated with simple cholecystectomy, and although comparison with radical cholecystectomy was unavailable, both groups showed 100% survival rates at 5 and 10 years. In the case of stage T1b, the extent of resection is controversial. Lee et al. reported that radical cholecystectomy had no benefit over simple cholecystectomy, whereas studies by Pilgrim et al. and Abramson et al. showed increased survival with radical resection, due to extraction of lymph node metastases and recurrence. There was no statistically significant difference according to surgical method in this study. There was no disadvantage to simple cholecystectomy, when compared with extended cholecystectomy according to median survival and 2-year survival rates in this study. As there were no deaths in the simple cholecystectomy subgroup, simple cholecystectomy in stage T1b could be regarded as curative resection.

There have also been disagreements on the extent of resection in stage T2. Ambramson et al. calculated mean 5-year cancer-specific survival of 61.3% in simple cholecystectomy alone group, but 87.5% in radical cholecystectomy group. Pilgrim et al. reported much higher 5-year survival rates in radical cholecystectomy (61% to 100%) when compared with simple cholecystectomy (19% to 50%). Zhu et al. and Kang et al. supported radical resection over simple resection, which showed higher 5-year survival rates in the T2 groups. On the contrary, Konstantinidis et al. reported that there was no significant difference between radical and simple cholecystectomy. In addition, Kohya et al. subdivided stage T2 patients into whether or not there was hepatic, biliary, lymphatic, venous, peri-neural or lymph node invasion, and proposed that radical resection was unnecessary in negative subgroups, whereas liver and/or biliary resection was needed when positive findings were present. Five year survival rates were confirmed to be higher in stage T2 radical resection subgroups in his study.

Stages T3 and T4 lead to poor prognosis, even after radical cholecystectomy. According to the French Surgical Association survey, 90% of patients with completed radical cholecystectomy expired within 12 months. Likewise, this study also had no significant difference in surgical method in the T3 subgroups, with 5 year survival rates at 40.9% in the T3 and 0% in the T4 subgroups. On the other hand, Kondo et al. reported T3, T4 with N1 patients were improved survival rate by lymph node dissection and with no detectable difference in 5-year survival rates between N0 (66%) and N1 (53%) patients.

In conclusion, CEA and T stage were independent prognostic factors significantly associated with patient survival in multivariate analysis. Although observation periods were short and number of cases was small, both simple and extended cholecystectomy showed similar survival rates in the T1b subgroups. Longer observation periods and more cases will be needed to confirm these conclusions.

REFERENCES

1. Jung KW, Park S, Kong HJ, et al. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2008. Cancer Res Treat 2011;43:1-11.
2. Zhu AX, Hong TS, Hezel AF, et al. Current management of gallbladder carcinoma. Oncologist 2010;15:168-181.
3. Cubertafond P, Gainant A, Cucchiaro G. Surgical treatment of 724 carcinomas of the gallbladder. Results of the French Surgical Association Survey. Ann Surg 1994;219:275-280.
4. Smith GC, Parks RW, Madhavan KK, et al. A 10-year experience in the management of gallbladder cancer. HPB (Oxford) 2003;5:159-166.
5. Moon HH, Yoon M. The survival rate of gallbladder carcinoma based on the presence of lymph node metastasis and the depth of the primary tumor invasion. Korean J Hepatobiliary Pancreat Surg 2008;12:128-133.
6. Konstantinidis IT, Deshpande V, Genevay M, et al. Trends in presentation and survival for gallbladder cancer during a period of more than 4 decades: a single-institution experience. Arch Surg 2009;144:441-447.
7. Liang JW, Dong SX, Zhou ZX, et al. Surgical management for carcinoma of the gallbladder: a single-institution experience in 25 years. Chin Med J (Engl) 2008;121:1900-1905.
8. Chan SY, Poon RT, Lo CM, et al. Management of carcinoma of the gallbladder: a single-institution experience in 16 years. J Surg Oncol 2008;97:156-164.
9. Misra S, Chaturvedi A, Misra NC, et al. Carcinoma of the gallbladder. Lancet Oncol 2003;4:167-176.
10. Chakravarty KD, Yeh CN, Jan YY, et al. Factors influencing long-term survival in patients with T3 gallbladder adenocarcinoma. Digestion 2009;79:151-157.

11. Park JI, Kim JS, Kim KH, et al. Analysis of prognostic factors affecting survival in patients with gallbladder cancer. Korean J Hepatobiliary Pancreat Surg 2010;14:173-183.

12. Kang SY, Lee SK, Kim JY, et al. Clinical features and prognostic factors influencing long-term survival in pT2 gallbladder carcinoma patients. Korean J Hepatobiliary Pancreat Surg 2008;12:173-179.

13. Abramson MA, Pandharipande P, Ruan D, et al. Radical resection for T1b gallbladder cancer: a decision analysis. HPB (Oxford) 2009;11:656-663.

14. Lee SE, Jang JY, Lim CS, et al. Systematic review on the surgical treatment for T1 gallbladder cancer. World J Gastroenterol 2011;17:174-180.

15. Pilgrim C, Usatoff V, Evans PM. A review of the surgical strategies for the management of gallbladder carcinoma based on T stage and growth type of the tumour. Eur J Surg Oncol 2009;35:903-907.

16. Kohya N, Kitahara K, Miyazaki K. Rational therapeutic strategy for T2 gallbladder carcinoma based on tumor spread. World J Gastroenterol 2010;16:3567-3572.

17. Kondo S, Takada T, Miyazaki M, et al; Japanese Association of Biliary Surgery; Japanese Society of Hepato-Biliary-Pancreatic Surgery; Japan Society of Clinical Oncology. Guidelines for the management of biliary tract and ampullary carcinomas: surgical treatment. J Hepatobiliary Pancreat Surg 2008;15:41-54.